20 results on '"Finetti, Pascal"'
Search Results
2. Prognostic and Predictive Value of LIV1 Expression in Early Breast Cancer and by Molecular Subtype.
- Author
-
de Nonneville, Alexandre, Finetti, Pascal, Boudin, Laurys, Denicolaï, Emilie, Birnbaum, Daniel, Mamessier, Emilie, and Bertucci, François
- Subjects
- *
GENE expression , *PROGNOSIS , *BREAST cancer , *ANTIBODY-drug conjugates , *CYCLIN-dependent kinase inhibitors , *PROGRESSION-free survival - Abstract
Background: LIV1 is a transmembrane protein that may become a new therapeutic target through the development of antibody–drug conjugates (ADCs). Few studies are available regarding the assessment of LIV1 expression in clinical breast cancer (BC) samples. Methods: We analyzed LIV1 mRNA expression in 8982 primary BC. We searched for correlations between LIV1 expression and clinicopathological data, including disease-free survival (DFS), overall survival (OS), pathological complete response to chemotherapy (pCR), and potential vulnerability and actionability to anti-cancer drugs used or under development in BC. Analyses were performed in the whole population and each molecular subtype separately. Results: LIV1 expression was associated with good-prognosis features and with longer DFS and OS in multivariate analysis. However, patients with high LIV1 expression displayed a lower pCR rate than patients with low expression after anthracycline-based neoadjuvant chemotherapy, including in multivariate analysis adjusted on grade and molecular subtypes. LIV1-high tumors were associated with higher probabilities of sensitivity to hormone therapy and CDK4/6 inhibitors and lower probabilities of sensitivity to immune-checkpoint inhibitors and PARP inhibitors. These observations were different according to the molecular subtypes when analyzed separately. Conclusions: These results may provide novel insights into the clinical development and use of LIV1-targeted ADCs by identifying prognostic and predictive value of LIV1 expression in each molecular subtype and associated vulnerability to other systemic therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. PVRIG Expression Is an Independent Prognostic Factor and a New Potential Target for Immunotherapy in Hepatocellular Carcinoma.
- Author
-
Birnbaum, David Jeremie, Picard, Maelle, Da Costa, Quentin, Delayre, Thomas, Finetti, Pascal, Cabaud, Olivier, Agavnian, Emilie, De Rauglaudre, Bernadette, Denicolaï, Emilie, Bertucci, François, and Mamessier, Emilie
- Subjects
IMMUNE checkpoint inhibitors ,KILLER cells ,GENE expression ,CELLULAR signal transduction ,RESEARCH funding ,HEPATOCELLULAR carcinoma ,IMMUNOTHERAPY - Abstract
Simple Summary: Hepatocellular carcinoma (HCC) represents the third cause of cancer-related death in the world, and identification of new prognostic factors and/or therapeutic targets remains a major issue. Recently, immune checkpoint inhibitors (ICIs) have opened promising therapeutic options for this disease. Using a large series of transcriptomic data of clinically annotated HCC samples, we provide evidence that the TIGIT/DNAM-1 axis, and notably the PVRIG molecule, might be an interesting therapeutic candidate for HCC tumors. Hepatocellular carcinoma (HCC) is a frequent and deadly cancer in need of new treatments. Immunotherapy has shown promising results in several solid tumors. The TIGIT/DNAM-1 axis gathers targets for new immune checkpoint inhibitors (ICIs). Here, we aimed at highlighting the potential of this axis as a new therapeutic option for HCC. For this, we built a large transcriptomic database of 683 HCC samples, clinically annotated, and 319 normal liver tissues. We interrogated this database for the transcriptomic expression of each member of the TIGIT/DNAM-1 axis and tested their prognostic value for survival. We then focused on the most discriminant one for these criteria, i.e., PVRIG, and analyzed the clinical characteristics, the disease-free and overall survivals, and biological pathways associated with PVRIG High tumors. Among all members of the TIGIT/DNAM-1 axis, PVRIG expression was higher in tumors than in normal liver, was heterogeneous across tumors, and was the only member with independent prognostic value for better survival. PVRIG High tumors were characterized by a higher lymphocytic infiltrate and enriched for signatures associated with tertiary lymphoid structures and better anti-tumor immune response. These results suggest that patients with PVRIG High tumors might be good candidates for immune therapy involving ICIs, notably ICIs targeting the TIGIT/DNAM-1 axis. Further functional and clinical validation is urgently required. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. PARP1 expression in soft tissue sarcomas is a poor‐prognosis factor and a new potential therapeutic target
- Author
-
Bertucci, Francois, Finetti, Pascal, Monneur, Audrey, Perrot, Delphine, Chevreau, Christine, Le Cesne, Axel, Blay, Jean-Yves, Mir, Olivier, Birnbaum, Daniel, Blay, Jean‐yves, Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Claudius Regaud, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR), Service d'Oncologie Médicale, Centre Léon Bérard [Lyon], Hôpital Cochin [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- Subjects
0301 basic medicine ,Genome instability ,Male ,Cancer Research ,DNA Repair ,[SDV]Life Sciences [q-bio] ,Poly (ADP-Ribose) Polymerase-1 ,0302 clinical medicine ,PARP1 ,Research Articles ,Aged, 80 and over ,Soft tissue sarcoma ,Sarcoma ,General Medicine ,Middle Aged ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,3. Good health ,PARP1 expression ,Gene Expression Regulation, Neoplastic ,Oncology ,030220 oncology & carcinogenesis ,soft tissue sarcoma ,PARP inhibitor ,Molecular Medicine ,Female ,Research Article ,Adult ,Adolescent ,DNA repair ,DNA damage ,Genomics ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,survival ,lcsh:RC254-282 ,03 medical and health sciences ,Young Adult ,Genetics ,medicine ,Humans ,Gene ,Aged ,Retrospective Studies ,business.industry ,medicine.disease ,Survival Analysis ,030104 developmental biology ,Cancer research ,prognosis ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
International audience; Soft tissue sarcomas (STSs) are aggressive tumors with few efficient systemic therapies. Poly(ADP-ribose) polymerase-1 (PARP1) inhibitors represent an emerging therapeutic option in tumors with genomic instability. The genomics of STSs is complex in more than half of cases, suggesting a high level of inherent DNA damage and genomic instability. Thus, STSs could be efficiently targeted with PARP inhibitors. Promising preclinical results have been reported, but few data are available regarding PARP1 expression in clinical samples. We examined PARP1 mRNA expression in 1464 clinical samples of STS, including 1432 primary tumors and 32 relapses, and searched for correlations with clinicopathological features, including metastasis-free survival (MFS). Expression was heterogeneous across the samples, not different between primary and secondary tumors, and was correlated to PARP1 DNA copy number. In the 1432 primary tumors, the 'PARP1-high' samples were associated with younger patients, more frequent locations at the extremities, superficial trunk and head and neck, more leiomyosarcomas and other STSs and less liposarcomas and myxofibrosarcomas, more grade 3, more high-risk CINSARC tumors, and more 'chromosomically instable' tumors. They were associated with shorter MFS, independently of other significant prognostic features, including the CINSARC signature. We found a strong involvement of genes overexpressed in the 'PARP1-high' samples in cell cycle, DNA replication, and DNA repair. PARP1 expression refines the prediction of MFS in STSs, and similar expression exists in secondary and primary tumors, supporting the development of PARP1 inhibitors.
- Published
- 2019
5. Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors
- Author
-
Aoki, Shuichi, Inoue, Koetsu, Klein, Sebastian, Halvorsen, Stefan, Chen, Jiang, Matsui, Aya, Nikmaneshi, Mohammad, Kitahara, Shuji, Hato, Tai, Chen, Xianfeng, Kawakubo, Kazumichi, Nia, Hadi, Chen, Ivy, Schanne, Daniel, Shigeta, Kohei, Kikuchi, Hiroto, Ramjiawan, Rakesh, Schmidt, Tyge Ce, Iwasaki, Masaaki, Yau, Thomas, Hong, Theodore, Quaas, Alexander, Plum, Patrick, Dima, Simona, Popescu, Irinel, Bardeesy, Nabeel, Munn, Lance, Borad, Mitesh, Sassi, Slim, Jain, Rakesh, Zhu, Andrew, Duda, Dan, Guo, Yuchen, Gabola, Monica, Lattanzio, Rossano, Paul, Conception, Pinet, Valérie, Tang, Ruizhi, Turali, Hulya, Bremond, Julie, Longobardi, Ciro, Maurizy, Chloé, da Costa, Quentin, Finetti, Pascal, Boissière-Michot, Florence, Rivière, Benjamin, Lemmers, Céline, Garnier, Séverine, Bertucci, François, Zlobec, Inti, Chebli, Karim, Tazi, Jamal, Azar, Rania, Blanchard, Jean-Marie, Sicinski, Peter, Lemmers, Bénédicte, Hahne, Michael, Gonçalves, Anthony, Guille, Arnaud, Adelaïde, José, Carbuccia, Nadine, Billon, Emilien, Sfumato, Patrick, Monneur, Audrey, Pécheux, Christophe, Khran, Martin, Brunelle, Serge, Mescam, Lenaïg, Thomassin-Piana, Jeanne, Poizat, Flora, Charafe-Jauffret, Emmanuelle, Turrini, Olivier, Lambaudie, Eric, Provansal, Magali, Extra, Jean-Marc, Madroszyk, Anne, Gilabert, Marine, Sabatier, Renaud, Vicier, Cécile, Chabannon, Christian, Pakradouni, Jihane, Viens, Patrice, André, Fabrice, Gravis, Gwenaelle, Popovici, Cornel, Birnbaum, Daniel, Chaffanet, Max, Amoozgar, Zohreh, Kloepper, Jonas, Ren, Jun, Tay, Rong En, Kazer, Samuel, Kiner, Evgeny, Krishnan, Shanmugarajan, Posada, Jessica, Ghosh, Mitrajit, Wong, Christina, Ferraro, Gino, Batista, Ana, Wang, Nancy, Badeaux, Mark, Roberge, Sylvie, Xu, Lei, Huang, Peigen, Shalek, Alex, Fukumura, Dai, Kim, Hye-Jung, Shigeta, Ayako, Staiculescu, Daniel, Zopf, Dieter, Fiebig, Lukas, Hobbs, Gabriela, Cobbold, Mark, Goyal, Lipika, Birnbaum, David, Mamessier, Emilie, Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, and Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Cancer Research ,Pancreatic ductal adenocarcinoma ,endocrine system diseases ,pancreatic cancer ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Biology ,lcsh:RC254-282 ,survival ,Article ,03 medical and health sciences ,0302 clinical medicine ,Downregulation and upregulation ,Pancreatic cancer ,Gene expression ,medicine ,Gene ,tumor location ,[SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Phenotype ,digestive system diseases ,Gene expression profiling ,medicine.anatomical_structure ,Oncology ,expression profiling ,030220 oncology & carcinogenesis ,Cancer research ,030211 gastroenterology & hepatology ,prognosis ,Pancreas - Abstract
The association between pancreatic ductal adenocarcinoma (PDAC) location (head vs. Body/Tail (B/T)) and clinical outcome remains controversial. We collected clinicopathological and gene expression data from 249 resected PDAC samples from public data sets, and we compared data between 208 head and 41 B/T samples. The 2-year overall survival (OS) was better for the head than for the B/T PDACs (44 vs. 27%, p = 0.043), especially when comparing tumors with similar TNM classification (T3/4N0M0: 67% vs. 17%, p = 0.002) or from the same molecular class (squamous subtype: 31% vs. 0%, p <, 0.0001). Bailey&rsquo, s molecular subtypes were differentially distributed within the two groups, with the immunogenic subtype being underrepresented in the &ldquo, B/T&rdquo, group (p = 0.005). Uni- and multivariate analyses indicated that PDAC anatomic location was an independent prognostic factor. Finally, the supervised analysis identified 334 genes differentially expressed. Genes upregulated in the &ldquo, head&rdquo, group suggested lymphocyte activation and pancreas exocrine functions. Genes upregulated in the &ldquo, group were related to keratinocyte differentiation, in line with the enrichment for squamous phenotype. We identified a robust gene expression signature (GES) associated with B/T PDAC location, suggesting that head and B/T PDAC are different. This GES could serve as an indicator for differential therapeutic management based on PDAC location.
- Published
- 2019
6. Inflammatory breast cancer in 210�patients: A retrospective study on epidemiological, anatomo‑clinical features and therapeutic results
- Author
-
Manai, Maroua, Finetti, Pascal, Mejri, Nesrine, Athimni, Salma, Birnbaum, Daniel, Bertucci, François, Rahal, Khaled, Gamoudi, Amor, Chaffanet, Max, Manai, Mohamed, Boussen, Hamouda, Bidaut, Ghislain, Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Abderrahmen Mami, Institut Salah Azaiez de Cancer, Université de Tunis El Manar (UTM), Inst Carcinol Salah Azaiz Tunis, Unité de Biochimie et Biologie Moléculaire, Faculté des Sciences Mathématiques, Physiques et Naturelles de Tunis (FST), Université de Tunis El Manar (UTM)-Université de Tunis El Manar (UTM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, and Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU)
- Subjects
0301 basic medicine ,Cancer Research ,medicine.medical_specialty ,Axillary lymph nodes ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,chemotherapy response ,[SDV.BC]Life Sciences [q-bio]/Cellular Biology ,Inflammatory breast cancer ,Gastroenterology ,survival ,histology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Epidemiology ,medicine ,Pathological ,[SDV.BC] Life Sciences [q-bio]/Cellular Biology ,Neoadjuvant therapy ,business.industry ,Cancer ,Retrospective cohort study ,Articles ,medicine.disease ,3. Good health ,[SDV] Life Sciences [q-bio] ,Exact test ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,immunohistochemistry ,epidemiology ,prognosis ,business ,inflammatory breast cancer - Abstract
International audience; To report epidemiological and anatomo-clinical features within a retrospective series of inflammatory breast cancer and to evaluate prognostic factors. This retrospective study included 210 Tunisian patients presenting a clinically diagnosed IBC, treated at the Institute Salah Azaiez (ISA) of Tunis, Tunisia, from 2008 to 2013. We collected data on epidemiology, anatomo-clinical and biological features and histologic response to neoadjuvant therapy. Overall and disease-free survivals were calculated by Kaplan-Meier method and compared by log-rank tests and Cox's models were used to identify prognostic factors impacting survival. The 210 IBC patients had a median age of 42 years (24-62) and 15% of them were aged less than 35 years. Mean age at menarche was 13 years and 45% had their 1st childbirth before 23 years. On histology, grades III represented 42% of cases, hormone receptors were negative in 59%, HER2 over-expressed in 32, 25% of our IBC cases had a triple negative profile and Ki-67 was >20% in 53% of cases. High pathological grade III was significantly correlated to TN subtype (58%) (Fisher's exact test, P=7.5×10-3). Further, high Ki-67 expression (>20%) was evident in the TN subtype (84%) (Fisher's exact test, P=3.7×10-4). After neoadjuvant therapy (and trastuzumab in 88 and 69% of HER2+ patients, respectively), we observed 49% of objective clinical responses and 35% of pathological complete response (pCR) and >3 axillary lymph nodes were invaded on a resected tumor in 55% of cases. Overall survival (OS) was associated with age at menarche (Wald-test, P=2.2×10-2) and metastases at diagnosis (Wald-test, P=2.4×10-2). Reaching a pCR was correlated with a better metastasis-free survival (MFS), (Fisher's exact test, P=3.6×10-2).
- Published
- 2018
7. Overexpression of Annexin A1 Is an Independent Predictor of Longer Overall Survival in Epithelial Ovarian Cancer.
- Author
-
MANAI, MAROUA, DOGHRI, RAOUDHA, FINETTI, PASCAL, MRAD, KARIMA, BOUABSA, RIHAB, MANAI, MOHAMED, BIRNBAUM, DANIEL, BERTUCCI, FRANÇOIS, CHARFI, LAMIA, and DRISS, MAHA
- Subjects
OVARIAN epithelial cancer ,ANNEXINS ,GENE expression ,IMMUNOHISTOCHEMISTRY ,GYNECOLOGY - Abstract
Background: Epithelial ovarian cancer (EOC) is the major gynecological cause of cancer deaths. Annexin A1 (ANXA1) protein has been implicated in the aggressiveness of several cancer types. Materials and Methods: This study retrospectively assessed ANXA1 expression in epithelial cells of 156 pre-chemotherapy EOC samples and 34 normal ovarian samples from patients treated at Salah Azaiez Institute. Using immunohistochemistry, ANXA1 expression was compared in normal versus cancer samples; correlations with clinicopathological features, including overall survival, were sought. Results: Fifty-two percent of tumor samples showed epithelial ANXA1 staining versus only 26% of normal samples (Fisher's exact test, p=0.00794). Epithelial ANXA1 expression was correlated with better overall survival in both univariate and multivariate analyses. Conclusion: The possible contribution of ANXA1 overexpression to EOC outcome may be relevant to therapeutic strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
8. PDL1 expression is associated with longer postoperative, survival in adrenocortical carcinoma.
- Author
-
Billon, Emilien, Finetti, Pascal, Bertucci, Alexandre, Niccoli, Patricia, Birnbaum, Daniel, Mamessier, Emilie, and Bertucci, François
- Subjects
- *
PROGRESSION-free survival , *CARCINOMA , *MULTIVARIATE analysis - Abstract
Adrenocortical carcinomas (ACCs) are heterogeneous cancers associated with a very poor prognosis. The improvement of prognostic tools and systemic therapy are urgently needed. Targeting the immune system using checkpoint inhibitors such as PD1/PDL1 inhibitors is an attractive novel therapeutic strategy for poor-prognosis tumors. Multiple clinical trials are ongoing, including in advanced ACC. However, PDL1 expression has been studied in ACC in only one heterogeneous series of 28 clinical samples. Here, we have retrospectively analyzed PDL1 mRNA expression in 146 clinical ACC samples and searched for correlations between expression and biological and clinicopathological data, including post-operative disease-free survival (DFS). PDL1 mRNA expression was heterogeneous across samples. "PDL1-high" tumors were not associated with the classical prognostic variables but were associated with longer DFS in both uni- and multivariate analyses. High PDL1 mRNA expression was associated with biological signs of the cytotoxic local immune response. Supervised analysis between "PDL1-high" and "PDL1-low" tumors identified a robust 370-gene signature whose ontology analysis suggested the existence in "PDL1-high" tumors of a cytotoxic T-cell response, however, associated with some degree of T-cell exhaustion. In conclusion, PDL1 mRNA expression refines the prognostication in ACC and high expression is associated with longer DFS. Clinical validation at the protein level and functional validation are required to fully understand the role of PDL1 in ACC. Reactivation of dormant tumor-infiltrating lymphocytes by PDL1-inhibitors could represent a promising strategy in "PDL1-high" ACCs, supporting the ongoing clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
9. WEE1 Dependency and Pejorative Prognostic Value in Triple‐Negative Breast Cancer.
- Author
-
de Nonneville, Alexandre, Finetti, Pascal, Birnbaum, Daniel, Mamessier, Emilie, and Bertucci, François
- Subjects
- *
TRIPLE-negative breast cancer , *PROGNOSIS , *CANCER cells , *BREAST cancer - Abstract
We then investigated the consequence of WEE1 chemical inhibition, which is less drastic than the WEE1 knock-out, in breast cancer cell lines according to the TN/non-TN subtypes. C/ Kaplan-Meier metastasis-free survival (MFS) in patients with breast cancer (n = 3454) according to the WEE1 expression-based class in TNBC (red curves) and in non-TNBC (blue curves). TNBC is the most aggressive molecular subtype of breast cancer, but patients with TNBC have less benefited from recognized molecular targets than patients with other subtypes. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
10. Inflammatory breast cancer in 210 patients: A retrospective study on epidemiological, anatomo-clinical features and therapeutic results.
- Author
-
Manai, Maroua, Finetti, Pascal, Mejri, Nesrine, Athimni, Salma, Birnbaum, Daniel, Bertucci, François, Rahal, Khaled, Gamoudi, Amor, Chaffanet, Max, Manai, Mohamed, and Boussen, Hamouda
- Subjects
- *
BREAST cancer , *HORMONE receptors , *CANCER patients , *MENARCHE , *RETROSPECTIVE studies - Abstract
To report epidemiological and anatomo-clinical features within a retrospective series of inflammatory breast cancer and to evaluate prognostic factors. This retrospective study included 210 Tunisian patients presenting a clinically diagnosed IBC, treated at the Institute Salah Azaiez (ISA) of Tunis, Tunisia, from 2008 to 2013. We collected data on epidemiology, anatomo-clinical and biological features and histologic response to neoadjuvant therapy. Overall and disease-free survivals were calculated by Kaplan-Meier method and compared by log-rank tests and Cox's models were used to identify prognostic factors impacting survival. The 210 IBC patients had a median age of 42 years (24–62) and 15% of them were aged less than 35 years. Mean age at menarche was 13 years and 45% had their 1st childbirth before 23 years. On histology, grades III represented 42% of cases, hormone receptors were negative in 59%, HER2 over-expressed in 32, 25% of our IBC cases had a triple negative profile and Ki-67 was >20% in 53% of cases. High pathological grade III was significantly correlated to TN subtype (58%) (Fisher's exact test, P=7.5×10−3). Further, high Ki-67 expression (>20%) was evident in the TN subtype (84%) (Fisher's exact test, P=3.7×10−4). After neoadjuvant therapy (and trastuzumab in 88 and 69% of HER2+ patients, respectively), we observed 49% of objective clinical responses and 35% of pathological complete response (pCR) and >3 axillary lymph nodes were invaded on a resected tumor in 55% of cases. Overall survival (OS) was associated with age at menarche (Wald-test, P=2.2×10−2) and metastases at diagnosis (Wald-test, P=2.4×10−2). Reaching a pCR was correlated with a better metastasis-free survival (MFS), (Fisher's exact test, P=3.6×10−2). [ABSTRACT FROM AUTHOR]
- Published
- 2019
11. Stromal Expression of MARCKS Protein in Ovarian Carcinomas Has Unfavorable Prognostic Value.
- Author
-
Doghri, Raoudha, Manai, Maroua, Finetti, Pascal, Driss, Maha, Agavnian, Emilie, Lopez, Marc, Elghardallou, Meriam, Charafe-Jauffret, Emmanuelle, Manai, Mohamed, Chaffanet, Max, Birnbaum, Daniel, Mrad, Karima, and Bertucci, François
- Subjects
OVARIAN cancer treatment ,KINASES ,EPITHELIAL cells ,STROMAL cells ,PROTEIN expression ,CANCER prognosis - Abstract
Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer. Identification of new therapeutic targets is crucial. MARCKS, myristoylated alanine-rich C-kinase substrate, has been implicated in aggressiveness of several cancers and MARCKS inhibitors are in development. Using immunohistochemistry (IHC), we retrospectively assessed MARCKS expression in epithelial and stromal cells of 118 pre-chemotherapy EOC samples and 40 normal ovarian samples from patients treated at Salah Azaiez Institute. We compared MARCKS expression in normal versus cancer samples, and searched for correlations with clinicopathological features, including overall survival (OS). Seventy-five percent of normal samples showed positive epithelial MARCKS staining versus 50% of tumor samples (p = 6.02 × 10
-3 ). By contrast, stromal MARCKS expression was more frequent in tumor samples (77%) than in normal samples (22%; p = 1.41 × 10-9 ). There was no correlation between epithelial and stromal IHC MARCKS statutes and prognostic clinicopathological features. Stromal MARCKS expression was correlated with shorter poor OS in uni- and multivariate analyses. Stromal MARCKS overexpression in tumors might contribute to cancer-associated fibroblasts activation and to the poor prognosis of EOC, suggesting a potential therapeutic interest of MARCKS inhibition for targeting the cooperative tumor stroma. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
12. Validation and comparison of the molecular classifications of pancreatic carcinomas.
- Author
-
Birnbaum, David J., Finetti, Pascal, Birnbaum, Daniel, Mamessier, Emilie, and Bertucci, François
- Subjects
- *
ADENOCARCINOMA , *GENE expression , *TUMORS , *MOLECULAR genetics , *BIOMARKERS - Abstract
Four molecular classifications of pancreatic ductal adenocarcinoma (PDAC), biologically and clinically relevant and based on gene expression profiles, were established in the recent years, including the Collisson's, Moffitt's ("tumor" and "stroma" classifications), and Bailey's classifications. The aim of this study was to validate the prognostic value of the Moffitt's classifications and to compare the Collisson's, Moffitt's, and Bailey's classifications in a large series of samples. We collected clinical and gene expression data of PDAC samples from 15 public data sets, resulting in a total of 846 primary cancer samples, including 601 with survival annotation. All samples were classified according to each of the four multigene classifiers. We confirmed the independent prognostic value of the Moffitt "tumor", Moffitt "stroma", and Bailey's classifications, but not that of the Collisson's classification. Despite a relatively low gene overlap, all classifications were associated with pathological grade, an important prognostic feature and reflect of intrinsic molecular characteristics of tumors. The concordance rate in term of "good-prognosis" vs. "poor-prognosis" prediction by classifiers was relatively high (from 73 to 86%) between the three "tumor" classifications based on tumor gene lists (Collisson, Moffitt "tumor", Bailey), but low (from 50 to 60%) with the Moffitt's stroma classification based on stroma genes. Multivariate analysis incorporating the four classifiers together retained as significant variables the Moffitt "stroma" and Bailey classifications, highlighting the complementarity of classifiers based on tumor epithelium (Bailey) and tumor stroma (Moffitt stroma). Our results reinforce the clinical validity of subtyping in PDAC, which should be regarded as a collection of separate diseases. Beside their clinical utility that remains to be demonstrated, the clinical interest of the subtypes, notably those from Bailey's and Moffitt's "stroma" classifiers that show independent prognostic value, will be reinforced by the identification of new biomarkers and/or therapeutic targets in each subtype for designing and testing novel specific targeted therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
13. A 25-gene classifier predicts overall survival in resectable pancreatic cancer.
- Author
-
Birnbaum, David J., Finetti, Pascal, Lopresti, Alexia, Gilabert, Marine, Poizat, Flora, Raoul, Jean-Luc, Delpero, Jean-Robert, Moutardier, Vincent, Birnbaum, Daniel, Mamessier, Emilie, and Bertucci, François
- Subjects
- *
SURGICAL excision , *CANCER patients , *PANCREATIC cancer , *CANCER chemotherapy , *ADJUVANT treatment of cancer , *ONCOLOGIC surgery , *COMBINED modality therapy , *LONGITUDINAL method , *PANCREATIC tumors , *PROGNOSIS , *SURVIVAL analysis (Biometry) , *GENE expression profiling - Abstract
Background: Pancreatic carcinoma is one of the most lethal human cancers. In patients with resectable tumors, surgery followed by adjuvant chemotherapy is the only curative treatment. However, the 5-year survival is 20%. Because of a strong metastatic propensity, neoadjuvant chemotherapy is being tested in randomized clinical trials. In this context, improving the selection of patients for immediate surgery or neoadjuvant chemotherapy is crucial, and high-throughput molecular analyses may help; the present study aims to address this.Methods: Clinicopathological and gene expression data of 695 pancreatic carcinoma samples were collected from nine datasets and supervised analysis was applied to search for a gene expression signature predictive for overall survival (OS) in the 601 informative operated patients. The signature was identified in a learning set of patients and tested for its robustness in a large independent validation set.Results: Supervised analysis identified 1400 genes differentially expressed between two selected patient groups in the learning set, namely 17 long-term survivors (LTS; ≥ 36 months after surgery) and 22 short-term survivors (STS; dead of disease between 2 and 6 months after surgery). From these, a 25-gene prognostic classifier was developed, which identified two classes ("STS-like" and "LTS-like") in the independent validation set (n = 562), with a 25% (95% CI 18-33) and 48% (95% CI 42-54) 2-year OS (P = 4.33 × 10-9), respectively. Importantly, the prognostic value of this classifier was independent from both clinicopathological prognostic features and molecular subtypes in multivariate analysis, and existed in each of the nine datasets separately. The generation of 100,000 random gene signatures by a resampling scheme showed the non-random nature of our prognostic classifier.Conclusion: This study, the largest prognostic study of gene expression profiles in pancreatic carcinoma, reports a 25-gene signature associated with post-operative OS independently of classical factors and molecular subtypes. This classifier may help select patients with resectable disease for either immediate surgery (the LTS-like class) or neoadjuvant chemotherapy (the STS-like class). Its assessment in the current prospective trials of adjuvant and neoadjuvant chemotherapy trials is warranted, as well as the functional analysis of the classifier genes, which may provide new therapeutic targets. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
14. Identification of Atypical Circulating Tumor Cells with Prognostic Value in Metastatic Breast Cancer Patients.
- Author
-
Lopresti, Alexia, Acquaviva, Claire, Boudin, Laurys, Finetti, Pascal, Garnier, Séverine, Aulas, Anaïs, Liberatoscioli, Maria Lucia, Cabaud, Olivier, Guille, Arnaud, de Nonneville, Alexandre, Da Costa, Quentin, Denicolai, Emilie, Pakradouni, Jihane, Goncalves, Anthony, Birnbaum, Daniel, Bertucci, François, and Mamessier, Emilie
- Subjects
BREAST cancer prognosis ,METASTASIS ,CANCER patients ,EPITHELIAL-mesenchymal transition ,CELL lines ,TUMOR markers - Abstract
Simple Summary: In this study we have isolated and analyzed atypical cells found in the blood of metastatic breast cancer patients using a micro-filtration technic. This technic, being very easy to implement, was also extremely useful for studying circulating tumors cells' (CTCs) heterogeneity in cancer patients. We highlighted three subsets of CTCs, with different independent unfavorable prognostic values for progression-free and overall survival. We demonstrated that these cells can further be analyzed by immunofluorescence to narrow their molecular profiles and identify specific characteristics. Moreover, we identified a subset of CTCs, for which positivity might be a useful stratification tool to select patients more susceptible to benefit from early clinical trials testing novel therapeutics, which frequently enroll late-stage, already heavily pre-treated and thus poor-responder patients. Circulating tumor cells have a strong potential as a quasi-non-invasive tool for setting up a precision medicine strategy for cancer patients. Using a second-generation "filtration-based" technology to isolate CTCs, the Screencell™ technology (Sarcelles, France), we performed a large and simultaneous analysis of all atypical circulating tumor cells (aCTCs) isolated from the blood of metastatic breast cancer (mBC) patients. We correlated their presence with clinicopathological and survival data. We included 91 mBC patients from the PERMED-01 study. The median number of aCTCs was 8.3 per mL of blood. Three subsets of aCTCs, absent from controls, were observed in patients: single (s-aCTCs), circulating tumor micro-emboli (CTM), and giant-aCTCs (g-aCTCs). The presence of g-aCTCs was associated with shorter progression free survival and overall survival. This study highlights the heterogeneity of aCTCs in mBC patients both at the cytomorphological and molecular levels. In addition, it suggests the usefulness of the g-aCTC subset as a prognostic factor and a potential stratification tool to treat late-stage mBC patients and improve their chances of benefiting from early clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. Revisiting the Concept of Stress in the Prognosis of Solid Tumors: A Role for Stress Granules Proteins?
- Author
-
Aulas, Anaïs, Finetti, Pascal, Lyons, Shawn M., Bertucci, François, Birnbaum, Daniel, Acquaviva, Claire, and Mamessier, Emilie
- Subjects
- *
PROTEIN metabolism , *BIOMARKERS , *GENE expression , *PSYCHOLOGICAL stress , *SURVIVAL , *TUMORS - Abstract
Simple Summary: Stress Granules (SGs) were discovered in 1999 and while the first decade of research has focused on some fundamental questions, the field is now investigating their role in human pathogenesis. Since then, evidences of a link between SGs and cancerology are accumulating in vitro and in vivo. In this work we summarized the role of SGs proteins in cancer development and their prognostic values. We find that level of expression of protein involved in SGs formation (and not mRNA level) could serve a prognostic marker in cancer. With this review we strongly suggest that SGs (proteins) could be targets of choice to block cancer development and counteract resistance to improve patients care. Cancer treatments are constantly evolving with new approaches to improve patient outcomes. Despite progresses, too many patients remain refractory to treatment due to either the development of resistance to therapeutic drugs and/or metastasis occurrence. Growing evidence suggests that these two barriers are due to transient survival mechanisms that are similar to those observed during stress response. We review the literature and current available open databases to study the potential role of stress response and, most particularly, the involvement of Stress Granules (proteins) in cancer. We propose that Stress Granule proteins may have prognostic value for patients. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
16. A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers.
- Author
-
de Nonneville, Alexandre, Finetti, Pascal, Adelaide, José, Lambaudie, Éric, Viens, Patrice, Gonçalves, Anthony, Birnbaum, Daniel, Mamessier, Emilie, and Bertucci, François
- Subjects
- *
BREAST cancer prognosis , *CELL proliferation , *MESSENGER RNA , *MULTIVARIATE analysis , *POSTOPERATIVE period , *PROTEIN-tyrosine kinases , *SURVIVAL , *GENE expression profiling - Abstract
Triple negative breast cancer (TNBC) represent 15% of breast cancers. Histoclinical features and marketed prognostic gene expression signatures (GES) failed to identify good- and poor-prognosis patients. Tyrosine kinases (TK) represent potential prognostic and/or therapeutic targets for TNBC. We sought to define a prognostic TK GES in a large series of TNBC. mRNA expression and histoclinical data of 6379 early BCs were collected from 16 datasets. We searched for a TK-based GES associated with disease-free survival (DFS) and tested its robustness in an independent validation set. A total of 1226 samples were TNBC. In the learning set of samples (N = 825), we identified a 13-TK GES associated with DFS. This GES was associated with cell proliferation and immune response. In multivariate analysis, it outperformed the previously published GESs and classical prognostic factors in the validation set (N = 401), in which the patients classified as "low-risk" had a 73% 5-year DFS versus 53% for "high-risk" patients (p = 1.85 × 10−3). The generation of 100,000 random 13-gene signatures by a resampling scheme showed the non-random nature of our classifier, which was also prognostic for overall survival in multivariate analysis. We identified a robust and non-random 13-TK GES that separated TNBC into subgroups of different prognosis. Clinical and functional validations are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
17. XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma.
- Author
-
Birnbaum, David Jérémie, Finetti, Pascal, Birnbaum, Daniel, Mamessier, Emilie, and Bertucci, François
- Subjects
- *
SECONDARY primary cancer , *TUMOR suppressor proteins , *ANAPLASTIC thyroid cancer , *ADENOCARCINOMA - Abstract
Pancreatic adenocarcinoma (PAC) is one of the most aggressive human cancers and new systemic therapies are urgently needed. Exportin-1 (XPO1), which is a member of the importin-β superfamily of karyopherins, is the major exporter of many tumor suppressor proteins that are involved in the progression of PAC. Promising pre-clinical data using XPO1 inhibitors have been reported in PAC, but very few data are available regarding XPO1 expression in clinical samples. Retrospectively, we analyzed XPO1 mRNA expression in 741 pancreatic samples, including 95 normal, 73 metastatic and 573 primary cancers samples, and searched for correlations with clinicopathological and molecular data, including overall survival. XPO1 expression was heterogeneous across the samples, higher in metastatic samples than in the primary tumors, and higher in primaries than in the normal samples. "XPO1-high" tumors were associated with positive pathological lymph node status and aggressive molecular subtypes. They were also associated with shorter overall survival in both uni- and multivariate analyses. Supervised analysis between the "XPO1-high" and "XPO1-low" tumors identified a robust 268-gene signature, whereby ontology analysis suggested increased XPO1 activity in the "XPO1-high" tumors. XPO1 expression refines the prognostication in PAC and higher expression exists in secondary versus primary tumors, which supports the development of XPO1 inhibitors in this so-lethal disease. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
18. Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors.
- Author
-
Birnbaum, David Jérémie, Bertucci, François, Finetti, Pascal, Birnbaum, Daniel, and Mamessier, Emilie
- Subjects
LYMPHOCYTES ,PANCREATIC physiology ,KERATINOCYTES ,CELL differentiation ,GENE expression ,MULTIVARIATE analysis ,PANCREATIC tumors ,STATISTICS ,SURVIVAL ,PHENOTYPES ,DESCRIPTIVE statistics ,DUCTAL carcinoma ,PROGNOSIS ,PHYSIOLOGY - Abstract
The association between pancreatic ductal adenocarcinoma (PDAC) location (head vs. Body/Tail (B/T)) and clinical outcome remains controversial. We collected clinicopathological and gene expression data from 249 resected PDAC samples from public data sets, and we compared data between 208 head and 41 B/T samples. The 2-year overall survival (OS) was better for the head than for the B/T PDACs (44 vs. 27%, p = 0.043), especially when comparing tumors with similar TNM classification (T3/4N0M0: 67% vs. 17%, p = 0.002) or from the same molecular class (squamous subtype: 31% vs. 0%, p < 0.0001). Bailey's molecular subtypes were differentially distributed within the two groups, with the immunogenic subtype being underrepresented in the "B/T" group (p = 0.005). Uni- and multivariate analyses indicated that PDAC anatomic location was an independent prognostic factor. Finally, the supervised analysis identified 334 genes differentially expressed. Genes upregulated in the "head" group suggested lymphocyte activation and pancreas exocrine functions. Genes upregulated in the "B/T" group were related to keratinocyte differentiation, in line with the enrichment for squamous phenotype. We identified a robust gene expression signature (GES) associated with B/T PDAC location, suggesting that head and B/T PDAC are different. This GES could serve as an indicator for differential therapeutic management based on PDAC location. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
19. The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers.
- Author
-
Bertucci, François, Finetti, Pascal, Birnbaum, Daniel, and Mamessier, Emilie
- Subjects
- *
BREAST cancer treatment , *MESSENGER RNA , *IMMUNE response , *CANCER chemotherapy , *LYMPHOCYTES - Abstract
Analysis ofPDL1mRNA expression in ∼5,500 breast cancers showedPDL1upregulation in 38% of basal tumors and 38% of inflammatory breast cancers (IBC). Upregulation, associated with signs of strong cytotoxic local immune response, was associated with a better survival in the basal or triple-negative subtypes, and with a better pathological response to chemotherapy in these subtypes and IBC. Reactivation of dormant tumor-infiltrating lymphocytes (TILs) by PD1/PDL1-inhibitors represents a promising strategy in these aggressive tumors. [ABSTRACT FROM PUBLISHER]
- Published
- 2016
- Full Text
- View/download PDF
20. Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer.
- Author
-
Birnbaum, David J., Bertucci, François, Finetti, Pascal, Birnbaum, Daniel, and Mamessier, Emilie
- Subjects
- *
PANCREATIC cancer , *GENOMES , *GENETIC mutation , *DNA repair , *CANCER chemotherapy - Abstract
Clinico-pathological factors fail to consistently predict the outcome after pancreatic resection for pancreatic ductal adenocarcinoma (PDAC). PDACs show a high level of inter- and intra- tumor genetic heterogeneity. A molecular classification should help sort patients into less heterogeneous and more appropriate groups regarding the metastatic risk and the therapeutic response, with the consequences of better predicting evolution and better orienting the treatment. PDAC can be classified based on mutational subtypes and 18gene alterations. Whole-genome sequencing identified mutational signatures, mutational burden and hyper-mutated tumors with specific DNA repair defects. Their overlap/similarities allow the definition of molecular subtypes. DNA and RNA classifications can be used in prognosis assessment. They are useful in therapeutic choice for they allow the design of approaches that can predict the respective drug sensitivity of each molecular subtype. This review provides a comprehensive analysis of available molecular classifications in PDAC and how this can help guide clinical decisions. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.